Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin combined with FOLFIRI + bevacizumab as second-line treatment for non-diabetic RAS-mutant metastatic colorectal cancer
ChiCTR2000037943Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Effect, Toxicity and 1 more. Started Aug 2020; status: recruiting.
02
Drugs
metformin
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000037943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037943.